News
News
News
Latest news
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
Business Wire
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
Business Wire
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
Business Wire
Precision Intelligence for Ophthmalogy
© 2026 Amaros, Inc. All rights reserved.
Precision Intelligence for Ophthmalogy
© 2026 Amaros, Inc. All rights reserved.
Precision Intelligence for Ophthmalogy
© 2026 Amaros, Inc. All rights reserved.
Precision Intelligence for Ophthmalogy
© 2026 Amaros, Inc. All rights reserved.
Advance ophthalmology with our innovative solutions.
• Accelerates enrollment and enhances protocol execution for CROs and trial teams.
• Enables personalized, precision care at the point of service.
• Reveals access gaps and growth opportunities for clinics and healthcare companies.
Advance ophthalmology with our innovative solutions.
• Accelerates enrollment and enhances protocol execution for CROs and trial teams.
• Enables personalized, precision care at the point of service.
• Reveals access gaps and growth opportunities for clinics and healthcare companies.
Advance ophthalmology with our innovative solutions.
• Accelerates enrollment and enhances protocol execution for CROs and trial teams.
• Enables personalized, precision care at the point of service.
• Reveals access gaps and growth opportunities for clinics and healthcare companies.